3RDD image
Entry Detail
PDB ID:
3RDD
Title:
Human Cyclophilin A Complexed with an Inhibitor
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2011-04-01
Release Date:
2012-03-21
Method Details:
Experimental Method:
Resolution:
2.14 Å
R-Value Free:
0.27
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Peptidyl-prolyl cis-trans isomerase A
Chain IDs:A
Chain Length:184
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities.
Nat Commun 7 12777 12777 (2016)
PMID: 27652979 DOI: 10.1038/ncomms12777

Abstact

Cyclophilins are peptidyl-prolyl cis/trans isomerases (PPIase) that catalyse the interconversion of the peptide bond at proline residues. Several cyclophilins play a pivotal role in the life cycle of a number of viruses. The existing cyclophilin inhibitors, all derived from cyclosporine A or sanglifehrin A, have disadvantages, including their size, potential for side effects unrelated to cyclophilin inhibition and drug-drug interactions, unclear antiviral spectrum and manufacturing issues. Here we use a fragment-based drug discovery approach using nucleic magnetic resonance, X-ray crystallography and structure-based compound optimization to generate a new family of non-peptidic, small-molecule cyclophilin inhibitors with potent in vitro PPIase inhibitory activity and antiviral activity against hepatitis C virus, human immunodeficiency virus and coronaviruses. This family of compounds has the potential for broad-spectrum, high-barrier-to-resistance treatment of viral infections.

Legend

Protein

Chemical

Disease

Primary Citation of related structures